SCHEMBL7141209

SCHEMBL7141209

COC(=O)c1ccc(N(C)C(=O)CN(C)C(=O)OCc2ccccc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.55
HPGD P15428 3/20 0.55
MAPT P10636 3/20 0.55
KDM4E B2RXH2 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
TSHR P16473 2/20 0.54
GAA P10253 2/20 0.54
NPC1 O15118 2/20 0.54
MAPK1 P28482 1/20 0.54
HSD17B10 Q99714 1/20 0.54
RAB9A P51151 4/20 0.51
LMNA P02545 2/20 0.45
KMT2A Q03164 3/20 0.44
PKM P14618 1/20 0.44
SLC6A2 P23975 1/20 0.44
SLC6A3 Q01959 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
NOTUM Q6P988 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7146929 0.86 ALDH1A1 (0.46) ALDH1A1HPGDMAPTKDM4ESMN1; SMN2
SCHEMBL7136756 0.84 ALDH1A1 (0.46) ALDH1A1HPGDMAPTMAPK1KMT2A
SCHEMBL206874 0.81 ALDH1A1 (0.57) ALDH1A1HPGDMAPTKDM4ESMN1; SMN2
SCHEMBL7141220 0.81 KMT2A (0.44) ALDH1A1HPGDMAPTKDM4ETSHR
SCHEMBL7141207 0.80 ALDH1A1 (0.54) ALDH1A1HPGDMAPTKDM4ESMN1; SMN2
SCHEMBL21069664 0.80 ABCB1 (0.51) ALDH1A1HPGDMAPTNPC1MAPK1
SCHEMBL21070691 0.80 ABCB1 (0.51) ALDH1A1HPGDMAPTNPC1MAPK1
SCHEMBL25461074 0.79 ABCB1 (0.55) ALDH1A1HPGDMAPTKDM4ENPC1
SCHEMBL7141206 0.79 CA1 (0.54) ALDH1A1HPGDMAPTKDM4ESMN1; SMN2
SCHEMBL6558020 0.79 ALDH1A1 (0.59) ALDH1A1HPGDMAPTKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1303485-A1 PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME F. HOFFMANN-LA ROCHE AG (CH) 2003-04-23 EP disclosed
US-6541638-B2 (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction HOFFMAN-LA ROCHE INC. 2003-04-01 US disclosed
US-20020049243-A1 Pyrrolidine derivatives HOFFMANN-LA ROCHE INC. 2002-04-25 US disclosed
WO-2002006222-A1 PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME F. HOFFMANN-LA ROCHE AG (CH) 2002-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049243-A1 Pyrrolidine derivatives PREP, PEPD, DNPEP ALDH1A1 767/4885HPGD 149/4885MAPT 2428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.